Podcasts about Cancer research

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On the next Charlotte Talks, we look at the treatment, screening and testing options for prostate cancer patients. We also look at promising new treatment research recently released by Duke University and hear from a prostate cancer survivor.

In this episode of the DAV Podcast, host Brian Buckwalter speaks with Dr. Ben Park, Director of the Vanderbilt Ingram Cancer Center, about the critical state of cancer research and its direct impact on military veterans. Dr. Park highlights the groundbreaking progress in cancer treatment, including innovative cellular therapies performed at the Nashville VA Hospital, and expresses grave concerns over recent, unprecedented funding cuts. He emphasizes that these cuts not only jeopardize patient lives and the continuation of life-saving research but also hinder the training of future medical professionals, ultimately undermining the commitment to provide veterans with the best possible care they deserve.

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

A report from Senator Bernie Sanders found that Trump officials cut $2.7B in NIH funding in the first three months of 2025, including a 31 percent cut to cancer research.

This episode teaches that innovation is born at the intersection of curiosity and persistence. Dr. Gudrun Stengel, co-founder and CEO of Alida Biosciences, reveals how her startup is transforming the landscape of RNA research through a novel technology called proximity barcoding. Dr. Stengel's story exemplifies the power of entrepreneurial spirit in driving scientific discovery, offering a glimpse into how one idea can reshape an entire field.At Alida Biosciences, Dr. Stengel and her team are pioneering new tools for detecting RNA modifications, a largely unexplored realm of epigenetics. Using their proximity barcoding platform, researchers can read multiple RNA modifications simultaneously, uncovering potential biomarkers and therapeutic targets for diseases like cancer, Alzheimer's, and diabetes. This technology bridges a critical gap in multiomics, allowing scientists to dive deeper into how epigenetic changes influence gene expression and cellular behavior.Beyond the lab, Dr. Stengel shares her experience as a first-time founder, balancing scientific rigor with startup life. From managing a team to fundraising, her journey underscores the importance of resilience, optimism, and maintaining a long-term vision. She also offers valuable advice for budding scientists, encouraging them to embrace challenges and remain persistent in the face of setbacks. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

The National Institutes of Health is the largest public funder of biomedical research in the world, but under the Trump administration, NIH is freezing funding to several universities, including Northwestern. One of the projects being delayed is cutting-edge research on ovarian and pancreatic cancer. Reset learns more about the effect of this freeze on patients and early career scientists with Josh Leonard, professor of chemical and biological engineering at Northwestern University. For a full archive of Reset interviews, head over to wbez.org/reset.

This week Bobbi Conner talks with MUSC's Dr. Ray DuBois about some of the cancer research currently underway at Hollings Cancer Center.

Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms related to hormone excess, including carcinoid syndrome and carcinoid heart disease, managing symptoms of functioning pancreatic neuroendocrine tumors, and also palliative interventions. Dr. Perez and Del Rivero share how to use this guideline in concert with the systemic therapy for tumor control in metastatic well-differentiated GEP-NETs guideline, and hope for the future for the treatment of gastroenteropancreatic neuroendocrine tumors. Read the full guideline, “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Transcript This guideline, clinical tools, and resources are available on ASCO.org. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in JCO Oncology Practice.        Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Kim Perez from Dana-Farber Cancer Institute and Dr. Jaydira Del Rivero from the Center for Cancer Research at the National Cancer Institute, co-chairs on “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Thank you for being here today, Dr. Del Rivero and Dr. Perez. Dr. Kim Perez: Thank you. Dr. Jaydira Del Rivero: Thank you so much for the invitation. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Perez and Dr. Del Rivero, who have joined us here today, are available online with the publication of the guideline in JCO Oncology Practice, which is linked in the show notes. So then to jump into the content here, first Dr. Del Rivero, could you provide an overview of the scope and purpose of this guideline? Dr. Jaydira Del Rivero: Yeah. Thank you so much. Well, first, we really wanted to thank ASCO for allowing us to develop these guidelines for the management of gastroenteropancreatic neuroendocrine tumors. I do want to mention that there is also another set of guidelines that I was very fortunate also to co-chair with Dr. Perez on the systemic management of gastroenteropancreatic neuroendocrine tumors. But when discussing these guidelines as well as with the different panelists, experts in this type of disease, we also realized that the management of these tumors are quite complex, not only from the management of the disease progression, but at the same time, management of the symptoms related to the hormone excess. And because of that, we like to thank ASCO for allowing us to then not only have a discussion on the systemic management of these tumors, but at the same time develop recommendations for the symptoms related to the different hormones that these neuroendocrine tumors may produce. These guidelines are for the management of grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. These guidelines include the management of the different aspects and the symptoms related to hormone excess, such as carcinoid syndrome, carcinoid heart disease, how to manage carcinoid crisis, as well as the different symptoms and how to manage the functional pancreatic neuroendocrine tumors and as well as provide recommendations in the different treatments for these tumor types, not only from the systemic management but also from the surgical management as well as for liver-directed therapy options and the different aspects in terms of the palliative care of these patients to improve not only the symptoms related to the hormone excess caused by these tumors, but as well as to improve the quality of life. Brittany Harvey: Absolutely. And I appreciate that overview. And yes, we'll link the guideline on the Systemic Therapy for Tumor Control for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors in the show notes for our listeners so that they can refer to that companion guideline as well. So then you just described the several different categories of recommendations that this guideline covers on symptom management. So, Dr. Perez, I'd like to start reviewing some of those key recommendations of that guideline. So, starting with what are the key recommendations for carcinoid syndrome and carcinoid heart disease? Dr. Kim Perez: Thank you Brittany. Yeah, I also want to thank ASCO for inviting us to do this podcast today. Just to start, I think these guidelines will really add to what's available in the literature to provide a kind of a quick look for the community provider to manage carcinoid-related symptoms. I think the highlights that I would point out are we've all been using somatostatin analogs for the last few decades to manage symptoms, but with the newer treatments that are now available, we tried to highlight what does the literature support in regards to PRRT, what does the literature support in regards to using systemic therapy for disease management, but also the benefits that you will get from a symptom management perspective using other modalities. I think the highlight really is it's a multidisciplinary approach. We are now considering surgery and embolization or interventional radiology as a critical piece. And I think the third that I'd highlight is the fact that sometimes we get too focused on carcinoid syndrome and the symptoms will actually, may result from other things. And the highlight in the algorithms that we've provided is what other things cause carcinoid-related diarrhea. And let's not forget about that because we will find ourselves treating and patients getting very frustrated with persistence of symptoms when in actuality, we should be treating something else that is causing a very similar symptom. For carcinoid heart disease, I think there are more and more guidelines that are now available to provide guidance there, but I think the major advances are that we should be utilizing heart assessment with echocardiogram with lab values such as BMP. But also critical to this is consulting with our cardiology colleagues and making sure that we're identifying heart related issues that are resulting from hormone excess sooner than later because interventions on the earlier side can really make a significant impact on quality of life and associated comorbidities and mortality. Brittany Harvey: Thank you for reviewing those key points for both carcinoid syndrome and carcinoid heart disease symptom management. So then the next set of recommendations. Dr. Del Rivero, what are the key highlights for symptom management of functioning pancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: Yes, it's very important to recognize the symptoms related to hormone excess due to pancreas neuroendocrine tumors. Up to 10% of pancreas neuroendocrine tumors may produce different hormones. Among those hormones can be insulin, gastrin, glucagon, somatostatin. So it's important to know and understand that based on what a neuroendocrine tumor is, they may produce different types of hormones. The importance of these guidelines is to also recognize some of these symptoms and how to address that, because it's not necessarily in these tumor types besides the management of metastatic disease, and know the different options that we recommend for metastatic disease from the systemic therapy, such as chemotherapy or targeted therapies or PRRT. It's important to recognize the symptoms because based on the symptoms we may recommend a different approach. That's something that is important to acknowledge and recognize. Moreover, in certain functional pancreas neuroendocrine tumors, as Dr. Perez mentioned, is a multidisciplinary approach. And it's important to also discuss these different cases with your endocrinologist. You may need to have an experienced endocrinologist to manage, for example, the excess of insulin. And also discuss your cases with a surgeon and interventional radiologist because some of these approaches can certainly improve the symptoms related to hormone excess. I understand that sometimes medical oncologists in the communities may not have access to the multidisciplinary approach or have the different teams that can manage these tumors, and that's the reason why with these guidelines we wanted to establish the understanding of different symptoms associated with the hormone excess to these neuroendocrine tumors as well as how to manage this. For example, in the case of insulinoma, I think for the medical oncologist it is important to know that the everolimus is an option to be used for these tumors, not only to manage tumor progressions related to this tumor type at the same time, because everolimus as a side effect causes hyperglycemia, that can also improve some of the symptoms related to the excess of insulin besides the somatostatin agonist. I think these recommendations will allow the medical oncologist to recognize the symptoms and based on what the symptoms cause, then you can have a different approach that could be added to the systemic therapies options as well. Brittany Harvey: Yes, beyond systemic therapy, it's important to be recognizing symptoms to provide an individualized approach for every single patient. So then, following that overview of symptom management for functioning pancreatic neuroendocrine tumors, Dr. Perez, what is recommended regarding palliative interventions for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, great question. So I think what's unique to neuroendocrine tumors is that the palliative approach really mirrors what we would be doing for symptom management. Some of these patients are living a very long time with carcinoid related symptoms. And so the approach that we take for the carcinoid symptom control is going to mirror the palliative piece of it. I think for those who develop a burden of disease related symptoms, I think it mirrors what we do across the board for all cancer-related complications. And so I think what we attempted to highlight here and included one of our colleagues who focuses specifically on the field of palliative care and neuroendocrine tumors, was to never really lose sight of what we've been doing to care for symptom management throughout the patient's journey and to always rereview the etiology of the symptoms, ensure that we don't focus solely on carcinoid-related issues, but also the symptom management that we would apply to all patients with cancer-related burden symptoms. Brittany Harvey: Definitely. I think that's a helpful approach to consider when thinking about how to manage these palliative interventions as well. So then Dr. Del Rivero, what should clinicians know as they implement these symptom management recommendations? Dr. Jaydira Del Rivero: Yes, thank you so much for that question. As we have discussed in the last 10 or 15 minutes, we have discussed the different approaches on the management of gastroenteropancreatic neuroendocrine tumors. Clinicians, I think it's important to know that neuroendocrine tumors is a quite complex disease because we're not only addressing the management of tumor growth, but we're also addressing the management of the symptoms related to hormone excess and the complexity associated with that. When medical oncologists or clinicians implement these recommendations it's to understand what symptoms these tumors may cause related to the hormone excess but at the same time, how do we approach those symptoms? As Dr. Perez said that I think is very important is to recognize the different types of diarrhea. It doesn't mean that if the patient has worsening diarrhea, it doesn't mean that this is related to disease progression. So it's important to recognize so that way you can address that, because the type of diarrheas can be related because of the lanreotide or somatostatin agonist, it could be because of the prior surgery. I think it's important to recognize those in order to address the symptom. And the same with the gastroenteropancreatic neuroendocrine tumors. It's important to know what hormones they produce because there are different measurements that may be added to the systemic management of these tumors. I think that there are two aspects here, and that's the reason why these guidelines were implemented in the sense that not only we're going to manage disease progression of these tumors, or how do we manage the metastatic disease of these tumors, but at the same time, how do we manage the symptoms related to the hormone excess and the different complications. Moreover, I think, as we discussed earlier, we need to manage these tumors in a multidisciplinary approach. And something very important is not like one size fits all, because the treatment recommendations, it will depend on different characteristics in terms of the tumor presentations. And hormone excess is one of the important aspects to recognize so that way we can implement these recommendations that will definitely help the quality of life of these patients. Brittany Harvey: Absolutely. And using these guidelines in concert with the systemic therapy guidelines is key. And then beyond this impact for clinicians that Dr. Del Rivero has just outlined, Dr. Perez, what does this new guideline mean for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, I think that's an important highlight of this guideline. It really gives patients a voice. I think it recognizes the fact that these symptoms can go unmanaged or mismanaged or just missed, and patients commonly will come in feeling very frustrated and feeling very ill. And I think it will provide them a means to open up a conversation with their providers and say, “Hey, this is what I'm experiencing. Let's talk about what's available. How does this apply to me?” And I think that can be very empowering. I think it's really hard nowadays with so many sources and resources online and patients are really left wondering what are the bullet points that they should be bringing to their clinician appointments? And I think that these guidelines provide them a good framework for those discussions. Brittany Harvey: Yes, bringing these discussion points for patients is very important to be able to have those resources. And we have some patient resources and information available on the website for this guideline and we can link that in the show notes for listeners. So then you've both touched on the importance of this guideline for improving quality of life and we continue to see advancements in this field. So Dr. Del Rivera, what are the outstanding questions regarding symptom management and tumor control for gastroenteropancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: I have to say whenever somebody asks me that question, the word that I will say is I feel hopeful, because more than 10 years ago we didn't have that many options for gastroenteropancreatic neuroendocrine tumors. And it has been in the last decade or so that there has been more developments in the management of these tumors as well as the understanding of the symptoms related to these tumors. But that said, yes, we do need more therapies for gastroenteropancreatic neuroendocrine tumors. Of the treatment options that we have, we all know in the field that even though we have disease control by using the different options for the systemic management of gastroenteropancreatic neuroendocrine tumors, we need options where we can achieve an objective response, especially for these tumor types. But there is a significant volume of disease and we see a lot of these patients with gastroenteropancreatic neuroendocrine tumors. And now where the field is going is to make some of these therapies more effective, to develop more therapies as well. For example, immunotherapies, a different type of immunotherapy understand the tumor immune microenvironment of these tumors in order to develop therapies as well. From the antibody drug conjugates, I think that's a new way to also address or treat these tumor types, understanding about the different markers found on these tumors that way they can be addressed in different ways. Now with the development of new therapies, I think that's something that can help us as well not only have disease control and as well as having an objective response, but having a better objective response can certainly also help with the symptoms related to hormone excess too. In terms of other therapies, I think some of the issues that we encounter are like the refractory carcinoid diarrhea and how do we manage this. We do have therapies that can help us control the diarrhea in the refractory settings, such as telotristat. Telotristat is one of the newer medications that can help us control the refractory diarrhea. But that said, despite this, that we still encounter situations where it's sometimes difficult to control. I think in those situations it will be good to understand more about the biology of these tumors as well and how we manage. If there is a different time or how do we implement these options. I think there is so much to learn. But that said, I feel we're in hopeful times. We're understanding more about these tumors so that way we can help us develop better therapies not only to have control of the tumor growth as well having control of the symptoms. And it's the same with the pancreas neuroendocrine tumors in the metastatic setting. Sometimes it may be difficult to control this hormone excess. But understanding these and having therapies that can achieve more of an objective response, I think that will definitely help us more and manage these patients. But one aspect I want to mention, and Dr. Perez also mentioned as well, the fact that we have these guidelines that help us understand about the different symptoms related to hormone excess and how to address it, I think is very important because having symptoms related to hormone excess can be detrimental to the quality of life on patients with neuroendocrine tumors that may necessarily be related to disease progression and having this information is so important. And I'm hopeful for the different therapies. There's different clinical trials ongoing for neuroendocrine tumors and especially in the field of PRRT. And a lot of more information will come with the different alpha-PRRT and combination therapy. So more information to come in the next couple of years. So this is, in my opinion, hopeful times for this field. Brittany Harvey: It's great to hear that you're hopeful for all the developments in this field and we'll look forward to the development and discovery of new therapies and further research and then, hopefully incorporate those updates into guidelines in the future. So I want to thank you both so much for your work to develop these guidelines and thank you for your time today. Dr. Del Rivero and Dr. Perez. Dr. Jaydira Del Rivero: Thank you so much for having us. Dr. Kim Perez: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. Rebecca Whelan, an associate professor of chemistry at the University of Kansas and member of KU Cancer Center's Cancer Biology research program. The discussion focuses on the limitations of the CA125 blood test for ovarian cancer detection and Dr. Whelan's groundbreaking research, which reveals new insights into the structure of the CA125 protein. Dr. Whelan explains how new DNA sequencing technologies and artificial intelligence, specifically the Alpha Fold program, have helped her team improve the understanding and detection of ovarian cancer. Additionally, Dr. Whelan talks about collaborative efforts to identify new biomarkers for early diagnosis of ovarian cancer and shares advice for young scientists interested in making a difference in medicine through chemistry. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about Dr. Whelan's research into CA125 Learn more about ovarian cancer  Read about ovarian cancer screening and diagnosis at KU Cancer Center Learn more about Dr. Rebecca Whelan

Dr. Michael Bauer, Medical Director at Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about the dangers of mixing alcohol and medications, a new study published in the Cancer Research journal suggests that early prostate cancer diagnoses can be made via a mere urine test, how artificial intelligence has been used in the hospital, the […]

Dr. Michael Bauer, Medical Director at Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about the dangers of mixing alcohol and medications, a new study published in the Cancer Research journal suggests that early prostate cancer diagnoses can be made via a mere urine test, how artificial intelligence has been used in the hospital, the […]

A recently published study by the National Cancer Institute (NCI) discovers a link between physical activity and cancer risk after gathering data from wrist sensors, which could help lead to major advances in cancer research. Alaina Shreves, predoctoral fellow at NCI's Division of Cancer Epidemiology and Genetics Metabolic Epidemiology Branch, said the findings come from accelerometer-measured physical activity, which associated low-intensity exercise with up to a 26 percent decreased risk of certain cancers. Shreves highlighted the importance of wrist sensor data in cancer prevention. She also shared her excitement about a new project involving wearable technologies to determine how walking patterns impact cancer development.

Recorded May 4, 2025   May the Fourth Be With You!!!!   In this Star Wars-themed episode, Anna and I go over the final 2 games of the Caps' first round series against the Montreal Canadiens. We also give a brief, non-specific preview of their next round series against the Carolina Hurricanes.   Sorry we're not being more specific, but, muchlike Coach Carbery we're keeping things close to the vest....much like Han Solo who may or may not have fired first.....   Follow the lead of Captain Alex Ovechkin and donate to the V Foundation for Cancer Research: https://donate.v.org/campaign/667859/donate   #ALLCAPS #JenayaTalksCaps #SportsOTHP #LockedOnCapitals #TheOfficialCapsChirpPodcast #SucramsCapitalsOffTheirChainPodcast #ThatsDCHockey          

May is World Cancer Research Month. We talk with Dr. Lucio Miele about where treatments stand now, the importance of funding new research, and how AI is helping with early detection.

* We talk about where cancer research and treatments stand now, the importance of funding new research, and how AI is helping with early detection. * Monday Morning Markets With Mark Rosa

Send us a textWelcome to Episode 29 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.How do we tackle inequities in cancer care? What role do collaborative networks play in ensuring better outcomes for patients and their families? And how can molecular tumour boards bridge the gap for those outside metropolitan areas, giving them access to life-saving treatments and clinical trials?To explore these critical questions, our Host Rachael Babin is joined by Professor Mark Shackleton—Director of Oncology at Alfred Health, Professor of Oncology at Monash University, Chair of Melanoma and Skin Cancer Trials Ltd, and Co-Director of the Monash Partners Comprehensive Cancer Consortium (MPCCC).The Monash Partners Comprehensive Cancer Consortium (MPCCC) is transforming cancer care by creating networks that ensure equitable access to precision oncology across Victoria, regardless of a patient's location.Did You Know?• The MPCCC Fellowship program embeds early-career oncologists in partner hospitals to build expertise and connections• The Precision Oncology Program has processed over 1,000 patient referrals• 20% of referred patients receive recommendations for targeted therapies matched to their cancer's molecular profile• 5% of patients connected to clinical trials they wouldn't otherwise access• Regular molecular tumour boards discuss 5-10 cases per session• MPCCC has delivered a significant increase in regional cancer patient referrals, especially from GippslandVisit our website for information on the simple referral process through the Omico CaSP program and access this incredible resource for your patients. So, let's dive into the groundbreaking work being done to break down barriers and expand access to precision oncology.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

Among the recipients of the Israel Prize this year is Prof. Yinon Ben Neriah of the Faculty of Medicine at the Hebrew University of Jerusalem, who was recognized for his groundbreaking research in cancer. A distinguished physician, immunologist, and leading cancer researcher, Ben-Neriah's pioneering work has significantly advanced understanding of the biological mechanisms linking chronic inflammation and cancer. Notably, his research identified key processes by which inflammation facilitates cancer development, leading to the creation of novel therapeutic strategies. He spoke to KAN reporter Naomi Segal. (Photo: Bruno Charbit)See omnystudio.com/listener for privacy information.

Policy issues—particularly tariffs—loom large as Q1 2025 earnings season rolls on, with Pfizer , Novartis, AstraZeneca and many more all reporting this week. On Pfizer's call, CEO Albert Bourla called the Trump administration's national security concerns “legitimate,” but objected to the proposed tariffs in general. Meanwhile, Novartis CEO Vas Narasimhan brushed off the tariff risk but expressed concern over President Donald Trump's desire to bring back the ‘Most Favored Nations' rule.  Meanwhile, cancer conference season is in full swing, with the American Association for Cancer Research's annual event continuing in Chicago. Merck, GSK, Boehringer Ingelheim, Roche and others have presented highly anticipated data from some of their cornerstone cancer drugs and other candidates.  Turning to the latest news out of the FDA, newly minted Commissioner Marty Makary gave his first two big press interviews last week, making statements that both jibed with and contradicted recent reporting. And in the midst of the ongoing Novavax vaccine saga, many have raised concerns that the FDA could become politicized under the watch of HHS Secretary RFK Jr.  Finally, check out this week's BioPharm Executive stories, including a deep dive into the trend toward mining innovative therapies from China and BioSpace's annual report on pharma CEO-to-employee pay ratios. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Akeso's drug, Ivonescimab, has received approval in China as a competitor to Merck's Keytruda. However, its prospects in the US, where Summit owns the rights, are uncertain. Merck KGaA is acquiring SpringWorks for $3.9 billion to enhance its rare disease and oncology pipelines. Keytruda has shown promising results in reducing negative events in head and neck cancer patients. The cell and gene therapy sector faces challenges post-Marks FDA exit, including tariffs and workforce cuts.Transitioning to the next news, Trilink Biotechnologies introduces custom sets of mRNA for screening studies. Steminent Biotherapeutics is set to showcase a novel therapy for spinocerebellar ataxia. The cell and gene therapy sector is facing a critical period after the exit of FDA director Peter Marks, with threats such as tariffs and workforce cuts. Experts are uncertain about the future but are hopeful that Marks' legacy will continue under new FDA commissioner Marty Makary.Moving on to the upcoming American Association for Cancer Research meeting, which will feature presentations from companies like Merck and Boehringer Ingelheim that could impact cancer treatment. The industry in the U.S. is experiencing significant changes under the Trump administration, while conditions of regulatory and economic turmoil are more common in non-western markets. Makary's first interviews as FDA commissioner have raised questions about the accuracy of his statements.Lastly, the biopharma industry is also dealing with setbacks such as disappointing trial results and safety concerns. Overall, the sector is facing challenges but remains hopeful for the future under new leadership.

- Green Tea and Cognitive Benefits (0:10) - Critique of Pharmaceuticals and Big Pharma (2:39) - Green Tea and Brain Health (4:31) - Speed Cubing and Cognitive Training (10:47) - Green Tea and Cancer Prevention (15:59) - Green Tea and Heavy Metal Detoxification (24:45) - L-Theanine and Anxiety Relief (30:04) - Catechins and Polyphenols in Green Tea (36:21) - Green Tea Extracts and Supplements (39:14) - Green Tea and Cancer Therapy (50:57) - Colloidal Silver and Its Benefits (1:11:38) - Silver Nanoparticles and Cancer Research (1:23:02) - Historical and Metaphysical Significance of Metals (1:26:08) - Economic and Political Implications of Metals (1:27:53) - Challenges and Opportunities in Health and Science (1:30:08) - Personal Reflections and Future Plans (1:37:17) - Final Thoughts and Gratitude (1:41:15) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month's American Academy of Neurology. On a special episode of the BioCentury This Week podcast, BioCentury's editors discuss the landscape for MG therapies, including anti-BLyS and APRIL therapy telitacicept from Remegen. Joining BioCentury's editors are Qing Zuraw, chief development officer of podcast sponsor RemeGen, and Amit Sachdev, PI on global trials of the biotech's therapy. BioCentury's editors also preview the American Association for Cancer Research annual meeting, where degraders and bispecifics are defining translational trends at this year's event. This episode of BioCentury This Week podcast was sponsored by RemeGen.View full story: https://www.biocentury.com/article/655751#biotech #biopharma #pharma #lifescience #AAN #AACR00:01 - Sponsor Message: RemeGen Co.01:02 - Myasthenia Gravis at AAN08:31 - RemeGen's Telitacicept18:03 - AACR: Targets and TrendsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Broadcast from KSQD, Santa Cruz on 04-24-2025: Dr. Dawn issues an alert about hair growth vitamins containing high doses of biotin that can interfere with important medical tests, explaining how biotin supplementation can cause false readings for thyroid function, troponin, parathyroid hormone, sex hormones, vitamin D, testosterone, PSA, and ferritin tests. Responding to an email about non-stick cookware safety, she examines various ceramic-based technologies claiming to be non-toxic, noting concerns about Teflon alternatives like Thermalon and ScanPan, and recommending cast iron as the safest option, particularly for households with pregnant women. A caller inquires about plant-based diets after hearing a radiation oncologist's claim that all animal products are harmful. Dr. Dawn advocates for a balanced approach rather than extreme positions, suggesting practical strategies for increasing vegetable consumption without laborious food preparation. She discusses counterintuitive findings in cancer research where advanced age can actually reduce cancer risk, explaining how aging cells produce a protein called NUPR1 that makes them iron-deficient and less able to regenerate, potentially offering insights for new therapeutic approaches. A caller asks about Dr. Gundry's claims regarding lectins in foods like almonds and peas, with Dr. Dawn explaining that while lectins are plant defense mechanisms that can be toxic in high amounts, moderate consumption is generally safe because the liver builds additional enzymes to process these compounds and this improves general detoxification. Dr. Dawn clarifies misconceptions about soy products, explaining that fermented options like tempeh have fewer anti-nutrients than raw soybeans (edamame). Tofu while not fermented, undergoes processing that reduces anti-nutrient properties by approximately 90%.

In this episode of the Bench to Bedside podcast Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses the critical topic of alcohol consumption and its link to cancer risk with Dr. Lauren Nye, medical oncologist at the cancer center and associate professor of Internal Medicine at the University of Kansas Medical Center. They delve into the recent advisory from the US Surgeon General highlighting the increased cancer risk associated with alcohol consumption, explore how alcohol can promote cancer development through various mechanisms, and offer practical advice for reducing alcohol intake. Dr. Nye underscores the importance of public awareness and the role of healthcare professionals in disseminating this information, while also emphasizing the need for sustainable lifestyle changes. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Read the US Surgeon General's Advisory “Alcohol and Cancer Risk” Read “Understanding Breast Cancer Prevention” by Dr. Lauren Nye on the KU Cancer Center blog Learn about cancer prevention and risk reduction on the KU Cancer Center website

Today's Headlines: The State Department is getting a major overhaul, with Secretary Marco Rubio slashing overseas posts and U.S.-based staff by 15%, calling the agency bloated and politically biased. Meanwhile, the Pentagon will soon require women in combat roles to meet the same physical standards as men under a new "sex-neutral" fitness test. Over at HHS, Secretary RFK Jr. is compiling a national autism registry using private medical records, aiming to prove the condition's cause by September. At Harvard, groundbreaking cancer research has stalled because ICE is detaining the scientist who wrote the analysis software—she's now fighting deportation to Russia. Student loan borrowers in default could see their wages garnished starting in May, ending a pandemic-era pause. And Tesla reported a 71% drop in profits, partly due to Elon Musk's political baggage—but its carbon credit sales are booming. Resources/Articles mentioned in this episode: NY Times: Marco Rubio Shares Plans for Overhaul of State Department  NY Times: Female Soldiers Will Have to Pass ‘Sex-Neutral' Physical Test, U.S. Army Says The New Republic: RFK Jr. Set to Launch Disease Registry Tracking Autistic People  NBC News: New images could change cancer diagnostics, but ICE detained the Harvard scientist who analyzes them AP News: Student loans in default to be referred to debt collection, Education Department says WSJ: Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role Morning Announcements is produced by Sami Sage alongside Bridget Schwartz and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

(2:40) - Cancer-on-a-chip technology advances our understanding of how cancer operatesThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn more about the role of field programmable gate arrays (FPGAs) in the medical world! Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

The National Firefighter Registry is perhaps the most ambitious effort to date to understand the connection between firefighting and cancer. 

In this eye-opening video, Dr. Kristi Funk unveils the shocking truth about chicken and its connection to breast cancer. Learn how cooked meats like chicken contain harmful compounds like FIP, which fuel breast cancer growth. Discover how eliminating meat can drastically reduce these risks within just 24 hours. Don't miss this vital information for your health! #BreastCancerAwareness #HealthyEating #CancerPrevention

This week, I'm heading back to San Francisco's Chinatown for another delightfully chaotic mystery with our favourite sixty-something sleuth, Vera Wong. In Jesse Sutanto's latest novel, Vera Wong's Guide to Snooping on a Dead Man, the tea shop is still bustling, but what Vera's craving is just a little more excitement in her now much fuller life. When she encounters a young girl outside the police precinct, Vera senses a mystery in need of an answer, and she's back on the case! A locked briefcase, a viral social media moment, and a trail of secrets are far too much for the calming effects of a cup of her chrysanthemum tea.In this episode, I share my spoiler-free thoughts on this cosy, yet surprisingly dark sequel. I talk about why Vera continues to be such a compelling character and how this book explores found family and identity in the digital age.Whether you loved the first Vera Wong book or you're just dipping your toes into the world of cosy crime and cosy mysteries, this one has humour, heart, high-stakes sleuthing, and a grandmother who's got more guts than your average gumshoe. So, pop the kettle on, settle in, and let's chat all things books. Featured Links Vera Wong's Unsolicited Advice for Murderers Cosy Mysteries Playlist And don't forget, I'm back on Livestream for the Cure this year, on the 17th May. Tune in, take part, and please donate to this incredibly important cause. It's all in the name of Cancer Research.

Got Health Questions or Comments?

Scientific discovery happens in the lab—but it starts with curiosity and determination. In this episode of Absolute Gene-ius, we welcome Valeria Rangel, a PhD candidate at the University of California Irvine, who shares her research on acute lymphoblastic leukemia and the innovative ways digital PCR is helping uncover genetic patterns linked to cancer in Hispanic populations.Val's work focuses on Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia, a rare and aggressive form of cancer. She explains how her lab uses digital PCR to detect mutations with high precision, identify risk factors in certain populations, and even validate findings using CRISPR-Cas9 gene editing. Through her research, Val sheds light on the role of SNPs, methylation patterns, and translocations in leukemia progression—demonstrating how digital PCR is transforming the way we approach cancer research.Beyond the science, Val takes us on her personal journey, from struggling to break into research due to financial barriers to finding her passion in oncology. In this episode's Career Corner, she shares valuable advice for aspiring scientists, tips for landing research opportunities, and some of her most hilarious and humbling lab moments (yes, she has broken multiple pipettes).Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Can a glass of pomegranate juice really help slow the growth of prostate cancer? In this episode of The Moss Report, Ben Moss and Dr. Ralph W. Moss take a deep dive into the clinical research on pomegranate and cancer—especially prostate cancer. They explore landmark studies from Johns Hopkins and UCLA, uncover the political backstory behind the POMx extract, and offer practical guidance for integrating pomegranate into a cancer-fighting or preventative diet. Dr. Moss also shares his personal use of pomegranate powder, discusses antioxidant synergy, and introduces options that reduce sugar intake without sacrificing benefits. A compelling look at how traditional foods meet cutting-edge science. “Fill up that self-help space with scientifically documented ways to reduce your cancer risk.” – Dr. Ralph W. Moss

In this episode, host Jonathan Sackier speaks with Alexander Spira about cutting-edge advances in lung and colorectal cancer, including EGFR and KRAS-targeted therapies. They also discuss Spira's leadership in oncology research, his thoughts on the evolving ‘town-gown' dynamic in US medicine, and his hopes for the future of cancer care.  Timestamps:  00:00 – Introduction 01:50 – Most memorable family travel adventure 03:30 – What inspired you to go into oncology 05:49 – Three recent publications in lung cancer 07:02 – Real-world data on colorectal cancer 08:15 – Sex/gender differences in non-small cell lung cancer 11:53 – The science of KRAS mutations and drug development 15:07 – Accelerating diagnostics and access to therapies 17:13 – The ‘town-gown' debate in American healthcare 18:09- Three Wishes 

Amber Young's story isn't just about survival; it's about transforming daunting obstacles into powerful advocacy and support. In this episode of the Just DeW It podcast, Amber shares her inspiring journey from a regular dental check-up to a staggering diagnosis of a 5-centimeter tumor in her jawbone. Join Anne as she introduces Amber, whose determination led her through a grueling 22-hour surgery and a lengthy recovery process that reshaped not just her jaw but also her life. Despite the physical and emotional challenges, Amber emerged as a beacon of hope and an unwavering advocate for oral cancer awareness. Her journey underscores the power of early detection, community support through groups like the Oral Cancer Cause (OCC), and the critical importance of proactive health screenings. Beyond her personal experience, Amber casts a wider net on the narrative of oral cancer—its risks and the often-overlooked prevalence of this disease. She passionately discusses the integration of OCC into the prestigious Jimmy V Foundation for Cancer Research, enhancing outreach and research efforts. This episode encapsulates Amber's mission of turning life-threatening challenges into a life-affirming crusade, inspiring us to come together and witness the collective strength in community support and advocacy. What You'll Learn in This Episode: The critical importance of regular dental check-ups in early oral cancer detection. Amber's personal journey from diagnosis to her role as an advocate and health professional. The emotional and physical challenges faced during cancer treatment and recovery. The role and impact of the Oral Cancer Cause and its integration into broader cancer research initiatives. The significance of community support and advocacy in cancer awareness. Insights into maintaining personal well-being while navigating formidable health challenges. Let's listen in to Amber Young's journey through oral cancer and beyond! Learn More About Amber Young Here! Website: ayoungsurvivor.com Instagram: instagram.com/a_young_survivor_ Don't Forget to Sign Up for the Next DeW Retreat! 7th Annual DeW Life Retreat November 13-15, 2025 Charlotte, NC Want to get more involved? Join our membership and community below for exclusive perks! Join the DeW Life movement by becoming a member using this link.Join the Dental Entrepreneur movement by becoming a member using this link.Read the most recent edition of DeW Life Magazine here.Just DeW It Podcast is the official podcast of Dental Entrepreneur Women (DeW), founded by Anne Duffy, RDH. The mission of DeW is to inspire, highlight, empower, and connect all women in dentistry. To join the movement or to learn more, please visit dew.life. Together, we can DeW amazing things! References: Events/Communities: DeW Retreat 2025 Organizations: MUSC CDC GoFundMe American Academy of Oral Systemic Health (AAOSH) Health Coach Institute Jimmy V Foundation Oral Cancer Cause (OCC) Tools: CliftonStrengths Test Businesses/Brands: Ninja VELscope ABC People: Linda Miles Kathryn Gilliam Susan Cotton Robin Roberts Dr. Jeff Blackburn

The National Cancer Institute is exploring a new new tech-based treatment to help patients overcome a severe breathing disorder caused by the Human Papilloma Virus. Leaders from the agency's Center for Cancer Research — Dr. Clint Allen, a senior investigator, and Dr. Scott Norberg, an associate research physician — join us to discuss the findings from their recent study on the Recurrent Respiratory Papillomatosis, which can cause damage to the vocal cords and block airways, making it hard to breathe. Allen and Norberg shared details about the therapy, which uses a gorilla adenovirus based-technology to target the infection.

It started—as these stories so often do—with fatigue. At first, Jace Yawnick simply chalked it up to a busy life and a job requiring frequent travel. But then he noticed something: There were times the fatigue kicked in when he hadn't just gotten off a plane or done anything else particularly strenuous. “Intuitively,” Jace says, “something within me just knew something wasn't right.”  Then came the coughing and the back pain. It would be months—and more than one misdiagnosis—before doctors found the problem: Hodgkin lymphoma. As he processed the news of his diagnosis, Jace realized something: Facing cancer was not something he wanted to do by himself.    And so, when he started to chronicle his cancer experience online, he was simply looking for catharsis and camaraderie. He got both—along with a community of 700,000-plus followers who've followed his entire journey in hopes of seeing the moment he fulfilled a cherished goal: to ring the bell and declare himself cancer-free. In this episode, Jace talks to Your Stories host Dr. Mark Lewis about what it's like to share your cancer journey with thousands of people, the importance of advocating for yourself, and the role of community when it comes to conquering cancer. 

In this episode of The Chain, host Brandon DeKosky, associate professor, speaks with MIT colleague Jessica Stark, Underwood-Prescott career development professor, about glycans and why they are important in cancer research. Stark discusses how she became interested in immunology, what her PhD and post-doctoral training was like, her thoughts on singlets operating as part of a network of checkpoint molecules, and what's currently going on in glycobiology. She also talks about her keynote presentation at PEGS 2025 and what her new lab is working on. LINKS: MIT Department of Chemical Engineering MIT Department of Biological Engineering MIT 

Dr. Jana McHugh, Clinical Research Fellow at The Institute of Cancer Research, London, and the Royal Marsden Hospital, on a saliva test which helps identify men most at risk of prostate cancer.

Tuesday, April 8th, 2025Today, stocks take another dive as the Trump regime plays fast and loose with tariffs; the en banc panel for the DC Circuit Court of Appeals has reinstated Cathy Harris and Gwynne Wilcox to their jobs at the NLRB and MSRP; the North Carolina Supreme Court has temporarily blocked a lower court ruling requiring 65,000 people to cure their ballots; NIH researchers have made a cancer breakthrough but layoffs are delaying it; a second unvaccinated child has died of measles and RFK Jr uses it as an opportunity for a photo op; the Trump administration is planning on spending $45M on immigrant detention; Trump is planning a giant North Korean style military parade on his birthday; and the 4th Circuit Court of Appeals REFUSED to pause an order forcing the Trump admin to return Maryland father Kilmar Abrego Garcia back to the U.S. before midnight tonight; and Allison and Dana deliver your Good News.Thank You, Helix Sleep20% Off Sitewide when you go to HelixSleep.com/dailybeans.Thank You, IQBAR20% off all IQBAR products. Text dailybeans to 64000. Message and data rates may apply. See terms for details. Guest: Bobby Kogan@bbkogan - BlueSkyBobby Kogan - Center for American ProgressStories:Supreme Court delays midnight deadline for Trump administration to fix mistaken deportation of Maryland man | ABC NewsStock Market Volatility Hits 5-Year High As Wall Street Grapples With ‘Manmade' Tariff Problem | ForbesBessent flew to Florida to lobby Trump on tariff message - POLITICON.C. Supreme Court halts decision requiring verification of 65,000 votes in tight judicial race | NBC NewsNIH scientists have a cancer breakthrough. Layoffs are delaying it. | The Washington PostAppeals court halts Trump independent agency firings, spurring Supreme Court battle | The HillRFK Jr. visits Texas after second child dies of measles amid outbreak | The Washington PostTrump Administration Aims to Spend $45 Billion to Expand Immigrant Detention - The New York TimesTrump planning military parade through DC for 79th birthday | The HillGood Trouble:The Heritage Foundation DOGE Survey Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen. Check out other MSW Media podcastsShows - MSW MediaCleanup On Aisle 45 podSubscribe for free to MuellerSheWrote on SubstackThe BreakdownFollow AG and Dana on Social MediaAllison Gill Substack|Muellershewrote, BlueSky|@muellershewrote, Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, Twitter|@MuellerSheWroteDana GoldbergBlueSky|@dgcomedy, IG|dgcomedy, facebook|dgcomedy, danagoldberg.com, Twitter|@DGComedyShare your Good News or Good Trouble:dailybeanspod.com/goodFrom The Good News50501 South Dakota hosts ‘Hands Off' protests around the state | Dakota News NowBlue.Wing.Things to do in Case of COUP | YouTubeReminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen.Share your Good News or Good Trouble:https://www.dailybeanspod.com/good/ Check out other MSW Media podcastshttps://mswmedia.com/shows/Subscribe for free to MuellerSheWrote on Substackhttps://muellershewrote.substack.comFollow AG and Dana on Social MediaDr. Allison Gill Substack|Muellershewrote, BlueSky|@muellershewrote , Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, Twitter|@MuellerSheWrote,Dana GoldbergTwitter|@DGComedy, IG|dgcomedy, facebook|dgcomedy, IG|dgcomedy, danagoldberg.com, BlueSky|@dgcomedyHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?Supercasthttps://dailybeans.supercast.com/Patreon https://patreon.com/thedailybeansOr subscribe on Apple Podcasts with our affiliate linkThe Daily Beans on Apple Podcasts

New research into little known genetic mutation that is a risk factor for colon cancer. Also, an entrepreneur putting a new spin on needlepoint. Plus, an in-depth look behind the famous restaurant 'Din Tai Fung.' And, a company that is helping people sleep better at night. 

If there is something that we can all agree on wholeheartedly, it's "f*#$ cancer", right? This week, The Idiots bring on The Oncology Idiot, Dr. Christopher Fulkerson, who is at the forefront of cancer research for animals. Join us as we break down why there isn't a simple cure for cancer, the ways we are advancing in medicine, how the research process goes, and why animal research is great for humans, as breakthroughs with the former can jump to the latter.  Also, Dr. Kent ALMOST laughs at Cory's joke, so that's exciting. 

Clinicians and scientists are sounding alarms as the Trump administration slashes budgets at federal health agencies, including the NIH, which is the largest funder of cancer research in the world. We talk about the costs of the cuts, which researchers say could set back progress on treatments and cures by decades and jeopardize patients with advanced forms of cancer who rely on experimental clinical trials. Guests: Angus Chen, cancer reporter, STAT News Dr. Adil Daud, oncologist and melanoma specialist, UCSF Learn more about your ad choices. Visit megaphone.fm/adchoices

Our guest for this episode is the amazing Emma Campbell, aka Limitless Em - author, marathon runner, cancer survivor, and single mum of four. She tells us about her experience of being diagnosed with cancer when her triplets were just six months old. We discuss the best way to talk to kids about cancer, and Em's top tip for getting through a crisis. Follow Em on Instagram @limitless_em for more from her, including links to her excellent podcast, Open. She's running this year's London Marathon for Cancer Research as part of #TeamBowelBabe - have a look at her sponsorship page to donate. WE ARE BACK ON THE ROAD! Our brand new show Hot Mess is coming to theatres all over the country in 2025 and beyond. Many shows are SOLD OUT already so get your tickets NOW for Leeds, Sheffield, Stroud... Then we're off to Dunstable, Chelmsford, Worthing, Cardiff, Worcester, and many more... Visit scummymummies.com for dates and tickets. *WE HAVE A SHOP!* Visit scummymummiesshop.com for our ace t-shirts, mugs, washbags, sweatshirts and beach towels. FREE UK DELIVERY! We're on X (@scummymummies), Instagram, and Facebook. If you like the podcast, please rate, review and subscribe. Thank you for listening! Hosted on Acast. See acast.com/privacy for more information.

The Trump administration's budget-cutting efforts are having a big impact on research universities, even as those efforts face legal challenges. When it comes to medical research, universities often plan years in advance. We’ll hear what uncertainty in funding means for one Duke University research lab. But first: Genetic testing company 23andMe has filed for bankruptcy, and DoorDash is partnering with Klarna to offer buy now, pay later plans for food orders.

The Trump administration's budget-cutting efforts are having a big impact on research universities, even as those efforts face legal challenges. When it comes to medical research, universities often plan years in advance. We’ll hear what uncertainty in funding means for one Duke University research lab. But first: Genetic testing company 23andMe has filed for bankruptcy, and DoorDash is partnering with Klarna to offer buy now, pay later plans for food orders.

In this episode of the Beautifully Broken Podcast, Thomas P. Seager, PhD, an expert in sustainable engineering and co-founder of the Morozko Forge ice bath company, takes us on a journey of self-improvement and health benefits through cold plunge therapy. Seager discusses his personal journey, from overcoming obesity and emotional struggles to embracing cold exposure practices that positively impacted his testosterone levels, metabolic health, and mental wellness.He explains how cold therapy activates brown fat, improves mitochondrial health, and can aid in cancer prevention by inhibiting tumor growth. The conversation also covers the role of cold exposure in hormone balance, resilience, and the holistic approach to wellness. Seager's insights challenge conventional health practices and highlight the power of personal experience in improving overall health. Join us for an enlightening discussion on how cold plunge therapy contributes to physical, mental, and emotional well-being.CONNECT WITH THOMASInstagram: (https://www.instagram.com/seagertp/?hl=en)Uncommon Cold Book: (https://www.morozkoforge.com/uncommon-cold-book)Website: (https://www.morozkoforge.com/)Highlights:02:04 - Thomas Seager transitioned from civil engineering to health research.02:59 - Cold plunge therapy has significant health benefits and boosts testosterone.08:15 - Personal experiences can be more impactful than clinical trials.11:15 - High testosterone levels can protect against prostate cancer.13:31 - Cold exposure activates cold thermogenesis and rejuvenates mitochondria.18:38 - Community and connection are fostered through cold plunge practices.21:48 - Cold therapy can improve mental health and mood regulation.26:30 - Cold exposure may help in cancer prevention through various mechanisms.28:49 - The body benefits from holistic approaches to health and wellness.32:12 - Incorporating cold therapy can lead to positive health outcomes.35:28 - Exercise has proven anti-cancer effects and boosts immune function.39:07 - Patients should be empowered to take charge of their health.42:25 - A holistic approach to cancer treatment is essential.43:11 - Supportive care, like having a 'doula', is crucial for patients.49:44 - Brown fat plays a significant role in metabolic health and energy regulation. UPGRADE YOUR WELLNESSStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLEDhttps://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

In this episode of "Impact Theory with Tom Bilyeu," join Tom and his co-host Drew as they break into a whirlwind of current events, political intrigue, and innovations in technology. The dynamic duo dives headfirst into a plethora of topical discussions, starting with the transformative shift in perceptions toward Chinese innovation and its impact on global research, particularly in cancer treatments. They dissect the complicated narrative surrounding public reactions to government actions, showcasing how those on the ground often bear the brunt of political gamesmanship. The conversation takes an electrifying turn as Tom and Drew explore the new heights of space endeavors, applauding the Spirit of SpaceX for rescuing astronauts amidst political hurdles. Amidst this, they scrutinize the controversial chatter around Tesla's market moves and the implications for average investors. Get ready for an engaging session that promises to educate and provoke thought on these pressing issues. SHOWNOTES 00:00 Intro and Setting the Scene 00:48 Chinese Innovation and Cancer Research 06:12 Public Reactions and Political Missteps 11:54 SpaceX's Stellar Rescue Mission 17:30 Tesla Stock and Political Perceptions 21:00 Doxxing and Market Influence 23:58 Tariffs and China's Economic Edge 30:41 Housing Market Bubbles 40:25 Manufacturing and AI Impacts 49:28 Robotics and Advances in Technology 53:17 Satellites and Wildfire Detection CHECK OUT OUR SPONSORS Range Rover: Range Rover: Explore the Range Rover Sport at https://rangerover.com/us/sport Audible: Sign up for a free 30 day trial at https://audible.com/IMPACTTHEORY  Vital Proteins: Get 20% off by going to https://www.vitalproteins.com and entering promo code IMPACT at check out Thrive Market: ​​Go to https:thrivemarket.com/impact for 30% off your first order, plus a FREE $60 gift! Tax Network: Stop looking over your shoulder and put your IRS troubles behind you. Call 1-800-958-1000 or visit https://tnusa.com/impact ITU: Ready to breakthrough your biggest business bottleneck? Apply to work with me 1:1 - https://impacttheory.co/SCALE American Alternative Assets: If you're ready to explore gold as part of your investment strategy, call 1-888-615-8047 or go to https://TomGetsGold.com Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at https://mintmobile.com/impact.  DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details.  ********************************************************************** What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER SCALING a business: see if you qualify here. Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here. ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** Join me live on my Twitch stream. I'm live daily from 6:30 to 8:30 am PT at www.twitch.tv/tombilyeu ********************************************************************** LISTEN TO IMPACT THEORY AD FREE + BONUS EPISODES on APPLE PODCASTS: apple.co/impacttheory ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Learn more about your ad choices. Visit megaphone.fm/adchoices